
oct pm et
summari compani provid medic product servic primarili area orthoped
medic surgic medsurg well neurotechnolog spine
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct stock trade
look sale grow
follow
rise aid acquisit
activ expect organ growth across
major busi segment see robust
intern sale knee well
trauma extrem
expect instal mako robot
vs instal
respect instal
approxim mako robot global
september-end given
orthoped practic
think signific room grow
procedur full commerci releas
earli perform time
time
june agre acquir safeair
ag manufactur surgic smoke
acquir entellu medic maker minim
invas devic treatment airway
obstruct top prioriti
capit alloc merger acquisit
expect continu make tuck-in
share trade
ep attract valu
see long-term strength orthopaed
busi continu roll mako
competit foot market strong due
continu weak one primari
competitor zimmer biomet
medsurg see opportun continu
double-digit gain emerg market
market remain significantli
under-penetr expect continu
look acquisit opportun like
trauson orthoped manufactur china
acquir enhanc avenu
growth spine busi seem one
potenti area growth recent
increas exposur spine
agreement acquir august
risk recommend target price
competit failur integr acquisit
slowdown procedur growth
target reflect
multipl ep
estim slightli peer
oper competit area global
medic devic industri character rapid
technolog innov market share volatil
medical/surg suppli unit may vulner
reduct hospit capit equip spend
demand orthoped product becom
less immun econom cycl
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp one world lead medic technolog compani
compani offer innov product servic orthopaed revenu medic
surgic revenu neurotechnolog spine revenu aim
improv patient hospit outcom
orthopaed segment consist primarili implant use hip knee joint replac
trauma extrem surgeri goal deliv advanc implant design special
instrument make orthopaed surgeri recoveri simpler faster effect artifici
joint made cobalt chromium titanium alloy ceram ultra-high molecular weight
polyethylen implant patient whose natur joint damag arthriti
osteoporosi diseas injuri also sell trauma-rel product use primarili
fixat fractur result sudden injuri includ intern fixat devic nail plate
screw extern fixat devic pin wire connect bar receiv
clearanc unit state food drug administr fda mako total knee applic
robotic-arm assist technolog complet full commerci launch one four
lead global competitor joint replac trauma extrem product three
inc depuy synth johnson johnson compani smith nephew
medic surgic medsurg segment product includ surgic equip navig
system instrument endoscop commun system endoscopi patient handl
emerg medic equip intens care dispos product medic reprocess
remanufactur medic devic sustain medic devic product use varieti
medic specialti mani competitor medsurg segment launch
next gener set power tool compris sagitt saw reciproc saw rotari drill
neurotechnolog spine product includ neurosurg neurovascular spinal implant devic
neurotechnolog offer includ product use minim invas endovascular techniqu
comprehens line product tradit brain open skull base surgic procedur
orthobiolog biosurgeri product includ synthet bone graft vertebr augment
product minim invas product treatment acut ischem hemorrhag stroke
one five lead global competitor neurotechnolog four johnson
 johnson terumo corpor inc one five lead global competitor spine
four sofamor danek inc subsidiari depuy synth
inc globu medic inc
corpor strategi seek achiev sale growth high-end medic technolog
med-tech industri maintain capit alloc strategi priorit acquisit
dividend share repurchas invest million acquisit paid million
dividend repurchas million share success acquisit tend
small rel market capit
decemb announc definit merger agreement acquir entellu medic medic
technolog compani make product design minim invas treatment variou ear nose
throat diseas state million septemb also acquir novadaq technolog
inc lead develop fluoresc imag million
specif lot product respons warn letter receiv food drug
administr fda resum ship product return full suppli capac end
product manufactur intens care dispos product acquir
financi trend achiev cumul annual growth rate compound-annual-growth-rate revenu
five year end revenu grew year-over-year billion typic
invest revenu research develop spent million
 march quarter net debt total capit low leverag debt
ebitda ratio gener posit cash flow oper least past five
year billion given financi posit see near-term difficulti
compani pursu strategi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
encourag continu improv mako robot sale see
double-digit sale growth result continu robust procedur
et cfra keep hold opinion share corpor
rais target in-lin
peer forward ep estim ep vs
ahead view rais ep estim
sale rose orthopaed medsurg neurotech
yet note growth partial off-set lower price result also
impact voluntari recal certain oral product
encourag result spite product recal hurrican impact
sold mako robot bring instal base robot /jeffrey
et cfra maintain hold opinion share corp
keep target in-lin peer
forward ep estim trim
ep estim report
voluntari product recal involv specif lot oral solut
manufactur third-parti supplier recal initi
due potenti cross-contamin oral solut manufactur
equip share non-pharmaceut product expect resum
ship product septemb return full suppli year end
rais target in-lin peer
forward ep estim ep vs
ahead estim rais ep estim
sale rose orthopaed
medsurg neurotechnolog spine see benefit
portfolio restructur aid acquisit drive growth also
agre acquir novadaq provid fluoresc imag technolog
instal mako robot help drive knee sale /jeffrey loo
analyst research note compani news
et cfra keep buy opinion share corpor
lift target slightli
peer ep estim ep vs
lower estim sale increas billion
primarili higher sale volum off-set slightli lower price
organ basi sale orthopaed segment grew year-over-year
medsurg neurotechnolog spine acquir
billion quarter ad spine portfolio synerg
neurotechnolog orthopaed busi placement
mako robot global season slow quarter vs placement
finish provid upgrad exist account sale
forc focu place mako robot new account also highlight
posit earli clinic data relat mako procedur think earli
strength mako robot suggest long runway growth
et cfra keep buy opinion share corpor
maintain target slightli
peer ep estim ep vs
higher estim rais ep
ep sale increas
organ billion organ basi sale orthopaed
segment grew year-over-year medsurg grew neurotechnolog
spine grew encourag placement mako robot
quarter compar mako total knee
procedur vs think
mako robot still signific room growth although rumor
acquir rumor expect
manag top prioriti capit alloc merger
strong buy buy day ago unconfirm
report stryker corpor approach
acquisit deni discuss regard potenti
acquisit howev disput approach think
still possibl deal given robust pipelin continu
view pipelin favor mani promis avenu growth
much near-term stock perform may hing success approv
launch lotu edg transcathet aortic valv replac
think success execut next step /kevin huang cfa
corpor rais target
slightli peer next-twelve-month ep estim
ep vs higher estim rais
ep reduc ep
sale increas organ billion organ
revenu grew orthopaed segment medsurg
neurotechnolog spine given stronger-than-expect quarter see
organ annual sale grow stronger averag
growth expect medic technolog industri view posit
syk competit posit opportun gain market share
given weak competitor inc
busi due manufactur complianc issu prevent
buy hold rais target price
above-p ep estim set
ep vs ahead view sale
rose organ growth orthopaed sale rose medsurg rose
neurotechnolog rose product return market
expect slowli regain market share throughout
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
